Welcome to our dedicated page for Neogen news (Ticker: NEOG), a resource for investors and traders seeking the latest updates and insights on Neogen stock.
Neogen Corporation reports developments tied to its food safety and animal safety businesses, including diagnostic tests, environmental monitoring products, veterinary products and related manufacturing operations. Company updates commonly cover foodborne pathogen detection, Listeria testing, AOAC method certification, Petrifilm manufacturing activity, and product quality or recall matters involving animal health products.
Neogen news also includes quarterly operating results, segment performance in Food Safety and Animal Safety, business transformation updates, leadership and compliance appointments, and governance matters. Its recurring disclosures connect scientific validation, manufacturing execution, customer markets and regulatory interactions across food safety, livestock, and pet health and wellness applications.
Neogen (NASDAQ: NEOG) will release its fourth-quarter fiscal year 2026 financial results before the market opens on Thursday, July 30, 2026. Company executives will host a webcast and conference call at 8:00 a.m. Eastern time to provide a financial overview and business update. Investors can access the call via toll-free and international dial-in numbers using Conference ID 741 914 740, or through the Investor Relations section of Neogen’s website, where a replay will be available after the event.
Neogen (NASDAQ: NEOG) expanded availability of FIFRA Section 2(ee) recommendations for Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol to support New World Screwworm response efforts.
Texas has approved these uses, and Neogen is making recommendations available in Florida to aid livestock and horse owners’ fly management programs.
Neogen (NASDAQ: NEOG) announced AOAC Performance Tested Methods℠ certification (No. 042604) for its Molecular Detection Assay - Listeria Right Now™, validating enrichment-free detection of viable and non-viable Listeria species on stainless steel.
The test delivers actionable results in about two hours, integrates with existing environmental monitoring workflows, and expands Neogen’s validated pathogen-detection portfolio.
Neogen (NASDAQ: NEOG) reported fiscal Q3 2026 revenue of $211.2M, down 4.4% year-over-year, with Food Safety up 2.6% and Animal Safety down 20.1% due to third-party supplier challenges. GAAP net loss was $17.0M (EPS $(0.08)); Adjusted EPS was $0.09. Adjusted EBITDA was $48.2M (22.8% margin). The company raised FY26 revenue guidance to $857–$860M and maintained Adjusted EBITDA guidance of ~$175M. Petrifilm manufacturing transition remains on track for November FY27 and a $160M Genomics divestiture to Zoetis is expected to close in 2Q27, with net proceeds ~$140M.
Neogen (NASDAQ:NEOG) appointed Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary effective immediately. Ms. Stacey brings more than 25 years of life sciences legal and compliance experience, including over 10 years as a public company chief legal officer and 5 years as a public company board member.
She previously served at Galera Therapeutics and held senior legal roles at Wistar Institute, Antares Pharma, FXI, Auxilium, and Aventis Behring. Ms. Stacey also serves on the board of Context Therapeutics (NASDAQ:CNTX).
Neogen (NASDAQ: NEOG) will release third-quarter fiscal 2026 results before market open on April 9, 2026. Management will host a webcast and conference call the same morning at 8:00 a.m. Eastern to provide a financial overview and business update.
Access details include toll-free and international dial-in numbers, a conference ID, and a live webcast via the company’s Investor Relations webpage; a replay will be available after the call.
Neogen (NASDAQ: NEOG) agreed to sell its global genomics business (GeneSeek) to Zoetis for $160 million, subject to customary closing adjustments. The divestiture, part of a portfolio review, is expected to close by the end of Neogen's first half of fiscal 2027 and is subject to regulatory approval and customary closing conditions.
GeneSeek reported approximately $90 million in sales in fiscal 2025. Net proceeds are expected to be used primarily for debt reduction, and Guggenheim Securities acted as exclusive financial advisor.
Zoetis (NYSE: ZTS) will acquire Neogen's animal genomics business for $160 million, enhancing its Precision Animal Health capabilities.
The purchase adds five global laboratories, expanded genotyping and sequencing platforms, and software tools; Zoetis expects to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Neogen (NASDAQ: NEOG) announced a voluntary nationwide recall of all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution packaged as 2mL/20mg and 10mL/50mg vials due to microbial contamination.
The recall cites reports of adverse events in horses after intraarticular use (inconsistent with labeled topical use). Neogen is working with the FDA and arranging product returns; customers should quarantine recalled product and contact AnimalHealth@neogen.com or 859-254-1221.
Neogen (NASDAQ: NEOG) reported Q2 FY2026 revenue of $224.7M (down 2.8% YoY) with core revenue +2.9% YoY. Net loss was $15.9M (loss per diluted share $(0.07)), while Adjusted Net Income was $22.6M and Adjusted EBITDA was $48.7M with an Adjusted EBITDA margin of 21.7%. Gross margin declined to 47.5% from 49.0% due to tariffs, inventory write-offs and mix. Food Safety core growth was positive; Animal Safety revenue declined 11.8% YoY. Cash was $145.3M with $800.0M debt. Company raised FY2026 guidance to $845M–$855M revenue and ~$175M Adjusted EBITDA.